Additionally, our cytokine analysis determined an uplifted level of inflammatory cytokines, such as VEGF, IL-6, and CCL2, that can cause the progression of the tumor and initiate CRS, which limits the treatment and has a negative impact on the outcome. The gene discussed is CCL2; the disease is congenital rubella syndrome.